Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josef Thaler

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Cancers|October 3, 2020
Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 TherapyFlorian Huemer, Gudrun Piringer, Verena Schlintl, et al.
Integrative Cancer Therapies|August 1, 2020
Influence of a Structured Exercise Training on Patients Reported Quality of Life in Colorectal Cancer Patients After Adjuvant Chemotherapy: A Pilot StudyGudrun Piringer, Bernhard Holzner, Beate Mayrbaeurl, et al.
BMC Cancer|January 5, 2018
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)Florian Huemer, Josef Thaler, Gudrun Piringer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 12, 2011
Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trialGudrun Resch, Alexander De Vries, Dietmar Öfner, et al.
Cancers|April 30, 2021
Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and AgeDora Niedersüß-Beke, Manuel Orlinger, David Falch, et al.
BMC Cancer|November 26, 2020
Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysisHolger Rumpold, Dora Niedersüß-Beke, Cordula Heiler, et al.
Wiener Klinische Wochenschrift|July 10, 2020
REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancerGudrun Piringer, Laurenz Vormittag, Leopold Öhler, et al.
European Journal of Gastroenterology & Hepatology|May 29, 2009
Germline mutation of the E-cadherin gene in three sibling cases with advanced gastric cancer: clinical consequences for the other family membersBeate Mayrbaeurl, Gisela Keller, Walter Schauer, et al.
Anticancer Research|May 7, 2017
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II StudyWolfgang Eisterer, Gudrun Piringer, Alexander DE Vries, et al.
Cancer Research|October 20, 2004
p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorderFrancis H Grand, Sonja Burgstaller, Thomas Kühr, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Cancers|October 3, 2020
Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 TherapyFlorian Huemer, Gudrun Piringer, Verena Schlintl, et al.
Integrative Cancer Therapies|August 1, 2020
Influence of a Structured Exercise Training on Patients Reported Quality of Life in Colorectal Cancer Patients After Adjuvant Chemotherapy: A Pilot StudyGudrun Piringer, Bernhard Holzner, Beate Mayrbaeurl, et al.
BMC Cancer|January 5, 2018
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)Florian Huemer, Josef Thaler, Gudrun Piringer, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 12, 2011
Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trialGudrun Resch, Alexander De Vries, Dietmar Öfner, et al.
Cancers|April 30, 2021
Clinical Effectiveness of Oncological Treatment in Metastatic Colorectal Cancer Is Independent of Comorbidities and AgeDora Niedersüß-Beke, Manuel Orlinger, David Falch, et al.
BMC Cancer|November 26, 2020
Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysisHolger Rumpold, Dora Niedersüß-Beke, Cordula Heiler, et al.
Wiener Klinische Wochenschrift|July 10, 2020
REGO-ACT: assessment of physical activity during treatment with regorafenib for metastatic colorectal cancerGudrun Piringer, Laurenz Vormittag, Leopold Öhler, et al.
European Journal of Gastroenterology & Hepatology|May 29, 2009
Germline mutation of the E-cadherin gene in three sibling cases with advanced gastric cancer: clinical consequences for the other family membersBeate Mayrbaeurl, Gisela Keller, Walter Schauer, et al.
Anticancer Research|May 7, 2017
Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II StudyWolfgang Eisterer, Gudrun Piringer, Alexander DE Vries, et al.
Cancer Research|October 20, 2004
p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorderFrancis H Grand, Sonja Burgstaller, Thomas Kühr, et al.
Pageof 8